Illness Severity Associated with Comorbid Substance Use Disorders in Schizophrenia: An Electronic Health Record Study


Patel R1, Chan KMY2, Valko M3, Guruswamy G4, Ker S2, Batra G2, Kollins SH2, Rentería ME2
1King's College London, New York, NY, USA, 2Holmusk, New York, NY, USA, 3Holmusk, ARLINGTON, VA, USA, 4Holmusk, Herndon, VA, USA


: Substance use disorders (SUDs) can co-occur with schizophrenia, but little is known about their associations with illness severity. We analyzed electronic health record (EHR) data to determine the prevalence of comorbid SUDs in people with schizophrenia and their associations with illness severity.


: Data from the MindLinc EHR dataset were analyzed using NeuroBlu. A cohort of adults with a diagnosis of schizophrenia (ICD-10 F20*) was assembled. The exposure was defined as the presence of a comorbid SUD. The outcome measure was severe illness defined as a Clinical Global Impression Severity (CGI-S) score of 5 or greater documented within 30 days of schizophrenia diagnosis. Age, gender, race, marital status, employment status and year of schizophrenia diagnosis were included as covariates in a multivariable logistic regression analysis.


: A total of 13,634 adults with schizophrenia were included (F10* alcohol: 8.8%; F11* opioid: 2.1%; F12* cannabis: 7.2%; F14* cocaine: 3.7%; F15* stimulant: 1.2%; F17* nicotine: 1.8%) of which 12,676 (93.0%) had a documented CGI-S score. Comorbid cannabis use disorder (F12*) was associated with greater illness severity (mean CGI-S: 4.89; odds ratio: 1.68, 95% CI 1.32 to 2.14, p<0.001) and comorbid opioid use disorder (F11*) was associated with lower illness severity (mean CGI-S: 4.23; OR: 0.56, 0.37 to 0.83, p=0.004) compared to patients without comorbid SUD (mean CGI-S: 4.25).


: Comorbid SUDs vary in their associations with illness severity. Comorbid cannabis use disorder is associated with greatest illness severity consistent with its potential etiological role in schizophrenia. Conversely, opioid use disorder is associated with least illness severity. This could reflect differences in the clinical characteristics and functioning of individuals who use opioids compared to those who use other substances. Further analyses of healthcare service utilization could address the degree to which different comorbid SUDs are associated with worse clinical outcomes.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)




Clinical Outcomes, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Clinician Reported Outcomes, Electronic Medical & Health Records


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now